Thyroid dysfunction in Turkish patients with chronic hepatitis C receiving peginterferon plus ribavirin in the period of 2005-2010
Interferon-α based therapy for chronic hepatitis C (CHC) is associated with thyroiditis and thyroid dysfunction (TD). This study investigated whether TD during pegylated interferon-α (PEG-IFN) plus ribavirin treatment favors sustained viral response (SVR), and also the association between TD and PEG...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2012-09-01
|
| Series: | Brazilian Journal of Infectious Diseases |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1413867012001316 |
| _version_ | 1819268009502441472 |
|---|---|
| author | Sener Barut Ozgur Gunal Unal Erkorkmaz Feyza Yildiz |
| author_facet | Sener Barut Ozgur Gunal Unal Erkorkmaz Feyza Yildiz |
| author_sort | Sener Barut |
| collection | DOAJ |
| description | Interferon-α based therapy for chronic hepatitis C (CHC) is associated with thyroiditis and thyroid dysfunction (TD). This study investigated whether TD during pegylated interferon-α (PEG-IFN) plus ribavirin treatment favors sustained viral response (SVR), and also the association between TD and PEG-IFN formulations. This retrospective study was performed in CHC patients who had received PEG-IFN plus ribavirin and had been followed for six months after treatment. Several factors were compared between patients with and without TD. 119 patients were included in the study. De novo incidence of TD was found to be 16.8%, and 16 of the 18 patients with TD achieved SVR. Although this rate was higher than patients without TD according to univariate analysis, logistic regression analysis revealed that there was not a significant association between TD and SVR, whereas baseline thyroperoxidase antibody (anti-TPO) positivity was the only significant predictor of TD. Moreover, TD was not associated with PEG-IFN type. Both interferon-α and hepatitis C virus (HCV) contribute to TD during antiviral therapy. It seems that there is no association between thyroid toxicity and viral clearance or type of PEG-IFN; however, anti-TPO positivity before treatment is the strongest predictor for TD during antiviral therapy. Keywords: Chronic hepatitis C, Peginterferon, Thyroid dysfunction, Sustained virologic response |
| first_indexed | 2024-12-23T21:26:15Z |
| format | Article |
| id | doaj.art-e5aecc0ff1064a26a13779f00811d228 |
| institution | Directory Open Access Journal |
| issn | 1413-8670 |
| language | English |
| last_indexed | 2024-12-23T21:26:15Z |
| publishDate | 2012-09-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Brazilian Journal of Infectious Diseases |
| spelling | doaj.art-e5aecc0ff1064a26a13779f00811d2282022-12-21T17:30:36ZengElsevierBrazilian Journal of Infectious Diseases1413-86702012-09-01165448451Thyroid dysfunction in Turkish patients with chronic hepatitis C receiving peginterferon plus ribavirin in the period of 2005-2010Sener Barut0Ozgur Gunal1Unal Erkorkmaz2Feyza Yildiz3Department of Infectious Diseases and Clinical Microbiology, Gaziosmanpasa University, Tokat, TurkeyDepartment of Infectious Diseases and Clinical Microbiology, Gaziosmanpasa University, Tokat, Turkey; Corresponding author at: Gaziosmanpasa Universitesi Tip Fakultesi, Infeksiyon Hastaliklari ve Klinik Mikrobiyoloji, 60100 Tokat, Turkey.Department of Biostatistics, Gaziosmanpasa University, Tokat, TurkeyDepartment of Infectious Diseases and Clinical Microbiology, Gaziosmanpasa University, Tokat, TurkeyInterferon-α based therapy for chronic hepatitis C (CHC) is associated with thyroiditis and thyroid dysfunction (TD). This study investigated whether TD during pegylated interferon-α (PEG-IFN) plus ribavirin treatment favors sustained viral response (SVR), and also the association between TD and PEG-IFN formulations. This retrospective study was performed in CHC patients who had received PEG-IFN plus ribavirin and had been followed for six months after treatment. Several factors were compared between patients with and without TD. 119 patients were included in the study. De novo incidence of TD was found to be 16.8%, and 16 of the 18 patients with TD achieved SVR. Although this rate was higher than patients without TD according to univariate analysis, logistic regression analysis revealed that there was not a significant association between TD and SVR, whereas baseline thyroperoxidase antibody (anti-TPO) positivity was the only significant predictor of TD. Moreover, TD was not associated with PEG-IFN type. Both interferon-α and hepatitis C virus (HCV) contribute to TD during antiviral therapy. It seems that there is no association between thyroid toxicity and viral clearance or type of PEG-IFN; however, anti-TPO positivity before treatment is the strongest predictor for TD during antiviral therapy. Keywords: Chronic hepatitis C, Peginterferon, Thyroid dysfunction, Sustained virologic responsehttp://www.sciencedirect.com/science/article/pii/S1413867012001316 |
| spellingShingle | Sener Barut Ozgur Gunal Unal Erkorkmaz Feyza Yildiz Thyroid dysfunction in Turkish patients with chronic hepatitis C receiving peginterferon plus ribavirin in the period of 2005-2010 Brazilian Journal of Infectious Diseases |
| title | Thyroid dysfunction in Turkish patients with chronic hepatitis C receiving peginterferon plus ribavirin in the period of 2005-2010 |
| title_full | Thyroid dysfunction in Turkish patients with chronic hepatitis C receiving peginterferon plus ribavirin in the period of 2005-2010 |
| title_fullStr | Thyroid dysfunction in Turkish patients with chronic hepatitis C receiving peginterferon plus ribavirin in the period of 2005-2010 |
| title_full_unstemmed | Thyroid dysfunction in Turkish patients with chronic hepatitis C receiving peginterferon plus ribavirin in the period of 2005-2010 |
| title_short | Thyroid dysfunction in Turkish patients with chronic hepatitis C receiving peginterferon plus ribavirin in the period of 2005-2010 |
| title_sort | thyroid dysfunction in turkish patients with chronic hepatitis c receiving peginterferon plus ribavirin in the period of 2005 2010 |
| url | http://www.sciencedirect.com/science/article/pii/S1413867012001316 |
| work_keys_str_mv | AT senerbarut thyroiddysfunctioninturkishpatientswithchronichepatitiscreceivingpeginterferonplusribavirinintheperiodof20052010 AT ozgurgunal thyroiddysfunctioninturkishpatientswithchronichepatitiscreceivingpeginterferonplusribavirinintheperiodof20052010 AT unalerkorkmaz thyroiddysfunctioninturkishpatientswithchronichepatitiscreceivingpeginterferonplusribavirinintheperiodof20052010 AT feyzayildiz thyroiddysfunctioninturkishpatientswithchronichepatitiscreceivingpeginterferonplusribavirinintheperiodof20052010 |